Cabozantinib franchise sales over time

This page will track the sales of Exelixis' Cabozantinib oncology franchise. Cabozantinib is a targeted agent that inhibits the activity of receptor tyrosine kinases including MET, AXL, VEGF Receptors, and RET.

Cabozantinib Franchise Sales